Thelansis’s "Adenoid Cystic Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adenoid Cystic Carcinoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Adenoid cystic carcinoma (ACC) is a rare cancer, most often of the salivary glands. Many tumors harbor MYB or MYBL1 alterations, including MYB–NFIB fusions. ACC may grow slowly yet invade along nerves, recur, or spread to distant organs years after treatment. Symptoms depend on site and may include a mass, pain, numbness, or cranial nerve deficits. Localized disease is treated with surgery when feasible, often followed by radiotherapy. For recurrent or metastatic disease, management depends on growth, symptoms, and patient factors; selected patients may undergo local treatment or observation, while VEGFR-targeting tyrosine kinase inhibitors offer variable benefit. No systemic drug is FDA-approved specifically for recurrent or metastatic ACC. Investigational approaches include the MYB mRNA degrader REM-422, NOTCH inhibitors for pathway-activated tumors, and antibody-drug conjugates. Late relapse and limited durable systemic responses remain major challenges in advanced disease settings.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Adenoid Cystic Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Adenoid Cystic Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.